Allergan reaction

16 Sep 2014 By Robert Cyran

The Botox maker locked in a December date putting most of the board to a vote that may set the stage for a $51 bln hostile takeover. Before then, the focus will be on Valeant’s M&A-free results. It’s the buyer’s best hope, assuming Allergan doesn’t find another deal first.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)